November 2006
Worldwide Biotech;Nov2006, Vol. 18 Issue 11, p6
Trade Publication
The article reports that Swissmedic has approved telbivudine from Idenix Pharmaceuticals Inc. as treatment for chronic hepatitis B in Switzerland. The drug can be taken orally once a day, with or without food, to suppress replication of hepatitis B virus. Idenix chairman and CEO Jean-Pierre Sommadossi notes that the approval signifies a milestone for the company. The drug will be called Sebivo in Switzerland.


Related Articles

  • Novartis/Idenix: entering hepatitis B market.  // PharmaWatch: Monthly Review;Mar2006, Vol. 5 Issue 3, p31 

    The article reports that Novartis AG and Idenix Pharmaceuticals Inc. have submitted an application for European Union approval of telbivudine in chronic hepatitis B. It is the second application aimed at obtaining approval for the drug candidate, following a United States Food and Drug...

  • Idenix's HCV Drug On Hold; CEO Not Hopeful.  // Bioworld Week;7/23/2007, Vol. 15 Issue 30, p2 

    The article reports that nucleoside inhibitor valopicitabine drug for hepatitis C virus of Idenix Pharmaceuticals Inc. received a clinical hold order from the U.S. Food and Drugs Administration (FDA). Jean-Pierre Sommadossi, company's chairman, describes the Phase II data encouragement that...

  • Secret to Their Success. Ebeling, Thomas; Sommadossi, Jean-Pierre // BioPharm International;Oct2005 Supplement, p10 

    Presents an interview with Thomas Ebeling, Novartis Pharma AG CEO, and Jean-Pierre Sommadossi, Idenix founder, CEO and chairman, regarding the successful partnership between their two companies. Acceleration of the development of Idenix's hepatitis B drug; Most important thing done to make the...

  • Decisions Update.  // PharmaWatch: Biotechnology;Apr2007, Vol. 6 Issue 4, p10 

    The article offers news briefs concerning the approval of drugs. Astellas Pharma Inc.'s drug, Vaprisol, has been approved for the treatment of the blood sodium illness hypervolemic hyponatremia. Idenix Pharmaceuticals Inc.'s hepatitis B drug, Sebivo, has received approval in China. Marketing...

  • Idenix/Novartis: filing for hepatitis hope: Idenix and Novartis have submitted a new drug application to the FDA for telbivudine.  // PharmaWatch: Biotechnology;Feb2006, Vol. 5 Issue 2, p9 

    The article reports on the submission of a drug approval application by the biotechnology company, Idenix/Novartis to the United States Food and Drug Administration, for their antiviral drug, telbivudine. The drug candidate could become the fourth nucleoside reverse transcriptase inhibitor for...

  • Idenix's HCV Drug On Hold; 'Not Optimistic,' CEO Says. Osborne, Randall // BioWorld Today;7/16/2007, Vol. 18 Issue 136, p1 

    This article reports on the clinical hold ordered by the U.S. Food and Drug Administration (FDA) on Idenix Pharmaceuticals Incorporated's nucleoside inhibitor valopicitabine for hepatitis C. According to FDA findings, the drug has gastrointestinal side effects. Comments are made by Idenix...

  • Halting active hepatitis B.  // Cortlandt Forum;Feb2007, Vol. 20 Issue 2, p16 

    The article offers information about Tyzeka, an antiviral medication for the treatment of chronic hepatitis B. The active ingredient of Tyzeka is telbivudine, a thymidine nucleoside analog that has activity against hepatitis B virus reverse transcriptase. Tyzeka is being developed in...

  • Idenix Restructures To Focus On Therapy Bids In HCV, HIV. Osborne, Randall // BioWorld Today;10/1/2007, Vol. 18 Issue 190, p1 

    The article reports on the layoff of employees at Idenix Pharmaceutical Inc. Idenix Pharmaceuticals has laid off about one hundred employees as part of its restructuring effort to reduce expanses. Shares of Idenix decline on the word of restructuring. Meanwhile, the company is also retooling its...

  • Novartis: strengthening its infectious disease portfolio.  // PharmaWatch: Monthly Review;Mar2006, Vol. 5 Issue 3, p30 

    The article reports that the European Commission has approved Novartis AG's acquisition of Chiron Corp. The deal will improve Novartis' capabilities in vaccines, biopharmaceuticals and blood products. In addition, Novartis has submitted its Idenix Pharmaceuticals Inc. co-developed hepatitis B...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics